Latest Proprietary Technology News

Audeara Limited has reported record unaudited revenue of $3.64 million for the first 11 months of FY25, marking a 14% increase over FY24 and driven by new product launches and international partnerships.

TALi Digital has acquired the You Can Do It! Education program, integrating social-emotional learning into its digital health platform, supported by a $1.5 million equity raise to fund growth and technology reintegration.

FOS Capital has secured $3.7 million through a placement to fund its acquisition of Aldridge Traffic Systems, aiming to expand its footprint in the Australian lighting market. The deal includes key assets and intellectual property, positioning FOS for accelerated growth.

Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.

Anagenics Limited’s proprietary hair regrowth technology powers the newly launched Bouf Haircare brand, which has achieved over $500,000 in sales in its first week, setting the stage for a lucrative royalty stream.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

Papyrus Australia has secured a pivotal contract with UniSA to establish a Rapid Prototyping and R&D facility, advancing its sustainable packaging technology and commercial production plans.

Cardiex Digital Vascular Biomarkers announces a A$6.5 million equity raise to fund inventory, marketing, product development, and debt repayment, aiming to solidify its position in the expanding cardiovascular health market.

RareX Limited has partnered with Gega Elements to develop Australia’s inaugural integrated gallium supply chain, aiming to reduce reliance on Chinese supply and boost national critical mineral resilience.

Smartpay has reported an 8.5% rise in consolidated revenue for FY2025, driven by growth in Australia and a bold entry into New Zealand’s acquiring market. However, investments in technology and market expansion have weighed on EBITDA.

Zelira Therapeutics has published full results from a Phase I study showing its cannabinoid-based therapy ZLT-L-007 significantly outperforms Lyrica® in managing diabetic neuropathy pain and related symptoms.

Bell Financial Group delivered strong financial results for 2024, driven by growth in technology and product services, but early 2025 shows challenges from market volatility impacting core broking revenues.